Reference platform for diabetic retinopathy and other vascular complications

NewsGuard 100/100 Score

Integrated overview of important clinical and up-to-date basic research

This volume sets the stage for clinical experts working with diabetic patients as well as for researchers by describing the clinical presentations of retinopathy and their anatomical and functional correlates. It reviews currently available experimental models in animals. The impact of retinal pericytes, neuroglia and, specifically, Müller cells are discussed in detail.

The volume addresses a variety of current scientific discussions about mechanisms of damage such as growth factors and the VEGF/PEDF balance in the diabetic eye, the ocular renin-angiotensin system, and leukocyte interactions with the microvasculature among others. Stem and progenitor cells in the retina are discussed as potential directions for future investigation. The final chapters return to emerging clinical aspects, including current approaches to retinopathy as a predictor of cardiovascular risk and how knowledge can be translated from bench to bedside.

Bridging a widening gap in medical research between basic scientists, who may lose sight of the clinical presentations, and clinical researchers, who may grow unaware of the limits of experimental models, this volume serves as a reference platform for endocrinologists, diabetologists, ophthalmologists, as well as for scientists involved in clinical and basic research in diabetic retinopathy and other vascular complications of diabetes.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema